SS Innovations International, Inc. (Nasdaq: SSII) announced leadership changes effective November 6, 2026, as part of its management team strengthening for global expansion. The company appointed Gary G. Lo as Chief Financial Officer and promoted Dr. Vishwajyoti P. Srivastava to President.

Mr. Lo will serve as CFO and is based in the United States. He brings over three decades of financial leadership experience across medical technology, healthcare, robotics, and enterprise software. Prior to joining SS Innovations, Mr. Lo served as Chief Financial Officer of Subsense, Inc., a deep-technology brain-computer interface company, and previously held CFO roles at Beyeonics Vision and Cellares Corporation. He also held finance leadership positions at Johnson & Johnson, Siebel Systems, and Boston Scientific. Mr. Lo is a CPA and holds an MBA from the University of Chicago Booth School of Business.

Under the terms of his employment agreement, Mr. Lo will receive an annual base salary of $400,000 and is eligible for a cash bonus with a target amount of 50% of his base salary. He was also granted options to purchase 500,000 shares of the company's common stock under the 2026 Incentive Stock Plan. The options have an exercise price of $2.11 per share and vest over four years. If terminated without cause, he is eligible for severance of three months of base salary if terminated before the first anniversary, or six months if terminated on or after the first anniversary.

Dr. Vishwajyoti P. Srivastava, who previously served as Chief Executive Officer – Asia Pacific, has been appointed President and will relocate to Denver, Colorado. As President, Dr. Srivastava will oversee efforts to obtain regulatory approval for the SSi Mantra robotic surgical system in the United States and the European Union. The company authorized an increase in his base salary to $500,000. Dr. Srivastava is the son of the company's Chairman and CEO, Dr. Sudhir Srivastava.

The company noted that it is currently responding to queries from the U.S. Food and Drug Administration regarding its 510(k) premarket notification for the SSi Mantra system and is continuing its pathway toward CE marking certification in the European Union.